Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity for the development of medications aimed at preventing and treating opioid and stimulant use disorders and overdose. This initiative, structured as a cooperative agreement (UG3/UH3), seeks innovative preclinical and clinical research proposals that address significant gaps in the treatment landscape, particularly for opioid use disorder (OUD) and psychostimulant use disorder (PsUD). The program is critical in responding to the ongoing overdose crisis and aims to facilitate the FDA's approval of novel pharmacotherapeutics, including new chemical entities and biologics, with a funding ceiling of $3 million per year over a maximum of five years. Interested applicants can find more information and guidelines at the NIH grants website and should direct inquiries to grantsinfo@nih.gov, with applications accepted until September 1, 2025.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.